奥西替尼靶向治疗对非小细胞肺癌患者血清CEA、VEGF表达的影响

目的探讨奥西替尼靶向治疗对非小细胞肺癌(NSCLC)患者血清CEA、VEGF表达的影响。方法收集我院自2014年1月～2016年1月收治的70例晚期NSCLC患者,按随机数字表法分为两组,每组各35例。对照组给予传统PC方案化疗,观察组给予奥西替尼靶向治疗。观察并比较两组疗效、毒副反应及血清CEA、VEGF表达情况。结果观察组RR和DCR分别为85.71%、91.43%,均高于对照组的60.00%、71.43%(P0.05);治疗后,观察组血清CEA、VEGF水平均低于对照组(P0.05);观察组白细胞下降、肝功能损伤发生率低于对照组(P0.05);观察组1年生存率为77.14%、2年生存率为60.00%,均高于对照组的54.29%、34.29%(P0.05)。结论奥西替尼靶向治疗非小细胞肺癌近远期疗效确切,可抑制CEA、VEGF表达,延长生存期。

Effect of Oxetinib targeted therapy on serum CEA and VEGF expression in patients with non-small cell lung cancer

Objective To investigate the effect of oxitinib targeted therapy on serum CEA and VEGF in patients with non-small cell lung cancer(NSCLC).Methods 70 patients with advanced NSCLC who were admitted in our hospital from January 2014 to January 2016 were enrolled in the study.They were divided into two groups according to the random number table,with 35 cases in each group.The control group received chemotherapy with traditional PC regimen,and the observation group received oxitinib targeted therapy.The efficacy,toxicity and side effects,and serum CEA and VEGF expression between two groups were observed and compared.Results The RR and DCR of the observation group were 85.71%and 91.43%,respectively,which were higher than 60.00%and 71.43%of the control group(P<0.05).After treatment,the serum CEA and VEGF levels in the observation group were lower than those in the control group(P<0.05).The incidence of leukopenia and liver function damage in the observation group was lower than that in the control group(P<0.05).The 1-year survival rate of the observation group was 77.14%,and the 2-year survival rate was 60.00%,which was higher than that of the control group(54.29%,34.29%),P<0.05.Conclusion Oxytinib is effective in the treatment of non-small cell lung cancer in the short-term and long-term.It can inhibit the expression of CEA and VEGF and prolong survival.